C3J Therapeutics is a privately-held, clinical-stage biotechnology company focused on the discovery and development of novel targeted antimicrobials – synthetic bacteriophage (phage) and antimicrobial peptides. C3J is the worldwide, exclusive licensee from UCLA of the STAMP (Specifically Targeted Antimicrobial Peptides) Platform which mines bacterial genomes for targeting domains that confer pathogen-specific killing activity. To date, C3J has raised $137 million to develop our lead molecule (C16G2) and to expand our technological approach to target pathogens, including use of phage or phage structures that confer selective killing.
